Pharmacokinetics of Lenalidomide (Revlimid) in Patients With Multiple Myeloma and Impaired Renal Function.

Trial Profile

Pharmacokinetics of Lenalidomide (Revlimid) in Patients With Multiple Myeloma and Impaired Renal Function.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2016 Status changed from recruiting to completed.
    • 16 Feb 2009 Actual initiation date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 16 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top